Amicus Therapeutics (FOLD) announced fourth-quarter results, with improved revenue mainly due to Galafold and Pombiliti + Opfolda product sales.
For the fourth quarter, net income plunged to $1.69 million or $0.01 per share from $14.74 million or $0.05 per share in the last year.
The firm incurred a share-based compensation expense of $26.59 million, compared to $19.22 million last time.
Adjusted net income for the fourth quarter increased to $31.63 million or $0.10 per share from $29.19 million or $0.09 per share in the prior year.
Amicus Therapeutics commercial products include, Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a two-component treatment program for adults living with late-onset Pompe disease.
Net product revenue increased 24% to $185.21 million from $149.71 million in the prior year.
Galafold revenue increased 18% to $150.24 million from $127.50 million last year.
Pombiliti + Opfolda revenue climbed 57% to $34.97 million from $22.21 million in the prior year.
For the full year 2025, Adjusted net income increased to $96.76 million or $0.31 per share from $73.88 million or $0.24 per share in the prior year.
Net loss narrowed to $27.11 million or $0.09 per share from $56.11 million or or $0.18 per share in the prior year.
Net product sales jumped 20% to $634.21 million from $528.30 million in the year-ago.
Galafold revenue increased 14% to $521.70 million from $458.05 million last year.
Pombiliti + Opfolda revenue climbed 60% to $112.51 million from 70.24 million in the prior year.
Amicus cash, cash equivalents, and marketable securities increased to $293.5 million at December 31, 2025, as compared to $249.9 million in the prior year.
Notably, in December 2025, Amicus entered into a definitive agreement to be acquired by BioMarin Therapeutics for $14.50 per share in an all-cash transaction for a total value of approximately $4.8 billion. The transaction is expected to close in the second quarter of 2026.
FOLD has traded between $5.51 and $14.38 in the last one year.
FOLD closed Friday's trade down $0.07%, at $14.34.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.